1. Home
  2. WHG vs HUMA Comparison

WHG vs HUMA Comparison

Compare WHG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westwood Holdings Group Inc

WHG

Westwood Holdings Group Inc

N/A

Current Price

$15.52

Market Cap

173.6M

Sector

Finance

ML Signal

N/A

Logo Humacyte Inc.

HUMA

Humacyte Inc.

N/A

Current Price

$1.25

Market Cap

182.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WHG
HUMA
Founded
1983
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.6M
182.6M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
WHG
HUMA
Price
$15.52
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$10.00
AVG Volume (30 Days)
7.2K
5.9M
Earning Date
05-14-2026
01-01-0001
Dividend Yield
3.96%
N/A
EPS Growth
203.85
N/A
EPS
0.79
N/A
Revenue
$97,762,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$731.05
P/E Ratio
$18.99
N/A
Revenue Growth
3.21
N/A
52 Week Low
$14.37
$0.88
52 Week High
$18.99
$3.35

Technical Indicators

Market Signals
Indicator
WHG
HUMA
Relative Strength Index (RSI) 37.06 58.71
Support Level $14.51 $0.92
Resistance Level $15.70 $1.26
Average True Range (ATR) 0.60 0.09
MACD -0.17 0.01
Stochastic Oscillator 20.41 72.22

Price Performance

Historical Comparison
WHG
HUMA

About WHG Westwood Holdings Group Inc

Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: